What is Geno?
Genomatica, operating as Geno, is a biotechnology firm dedicated to remaking the world of everyday products through the power of clean manufacturing. By leveraging synthetic biology, the company develops sustainable, high-performance ingredients derived from plants and waste rather than non-sustainable sources like palm oil or petroleum. Geno has successfully commercialized solutions for spandex, plastics, and personal care products, while maintaining an active R&D pipeline for nylon and household cleaning agents. Its market position is defined by its ability to bridge the gap between laboratory-scale innovation and large-scale industrial production, effectively providing a drop-in solution for global manufacturers seeking to reduce their carbon footprint.
How much funding has Geno raised?
Geno has raised a total of $333.1M across 7 funding rounds:
Series A
$4M
Series B
$20M
Series C
$15M
Unspecified
$45M
Unspecified
$41.1M
Unspecified
$90M
Unspecified
$118M
Series A (2002): $4M, investors not publicly disclosed
Series B (2007): $20M led by Mohr Davidow Ventures and Draper Fisher Jurvetson (DFJ)
Series C (2010): $15M supported by Draper Fisher Jurvetson, Mohr Davidow Ventures, TPG Biotechnology Partners, and Alloy Ventures
Unspecified (2011): $45M, investors not publicly disclosed
Unspecified (2012): $41.1M, investors not publicly disclosed
Unspecified (2018): $90M with participation from Casdin Capital, Viking Global Investors, and Ginkgo Bioworks
Unspecified (2021): $118M led by Novo Holdings
Key Investors in Geno
Novo Holdings
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, focusing on long-term value creation in the life sciences sector.
Draper Fisher Jurvetson
Draper Fisher Jurvetson is a prominent venture capital firm with a global network, specializing in backing industry-changing catalysts across multiple technology sectors.
Casdin Capital
Casdin Capital is an investment firm that brings deep expertise and a long-term perspective to financing the next generation of life science and molecular innovation.
What's next for Geno?
With the support of its latest strategic investment, Geno is poised to expand its manufacturing capacity and accelerate the commercial deployment of its sustainable material portfolio. The company is expected to focus on scaling its nylon production capabilities and deepening its partnerships with global consumer brands looking to meet aggressive ESG targets. As the demand for bio-based materials continues to rise, Geno's platform-based approach to cell programming provides a significant competitive advantage, allowing for the rapid development of diverse chemical building blocks. Future growth will likely center on optimizing production efficiency and securing long-term supply agreements with major industrial players, further cementing its role as a critical infrastructure provider for the green economy.
See full Geno company page
